In contrast to Arp2/3 inhibitor assays on OT-I CTLs, purified CD8 cells derived from the ARPC1B-deficient patient showed reduced TCR signaling together with reduced degranulation and cytotoxicity compared with the HD population. This evidence concerns the gene ARPC1B and Huntington disease.